3 imperatives to transform health care in America. You're invited to watch it live

Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Complications

By Mayo Clinic staff

With vaginal atrophy, your risk of vaginal infections (vaginitis) increases. Atrophy leads to a change in the acidic environment of your vagina, making you more susceptible to infection with bacteria, yeast or other organisms.

Atrophic vaginal changes are associated with changes in your urinary system (genitourinary atrophy), which can contribute to urinary problems. You might experience increased frequency or urgency of urination or burning with urination. Some women experience more urinary tract infections or incontinence. Although stress incontinence is common among menopausal women, it doesn't appear to be caused by vaginal atrophy. The connection between estrogen deficiency and urinary problems remains unclear.

References
  1. Bachmann G, et al. Diagnosis and treatment of vaginal atrophy. http://www.uptodate.com/patients/index.html. Accessed Aug. 6, 2010.
  2. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. 2007;14:357.
  3. MacBride MB, et al. Vulvovaginal atrophy. Mayo Clinic Proceedings. 2010;85:87.
  4. Palacios S. Managing urogenital atrophy. Maturitas. 2009;63:315.
  5. Suckling JA, et al. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. 2006:CD001500.
  6. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause. 2010;17:194.
  7. Reed SD, et al. Vaginal, endometrial, and reproductive hormone findings: Randomized, placebo-controlled trial of black cohosh, multibotanical herbs and dietary soy for vasomotor symptoms: The Herbal Alternatives for Menopause (HALT) study. Menopause. 2008;15:51.
  8. Mehta A, et al. Vulvovaginal complaints. Clinical Obstetrics and Gynecology. 2008;51:549.
  9. Labrie F, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009;16:907.
  10. Panjari M, et al. DHEA for postmenopausal women: A review of the evidence. Maturitas. 2010;66:172.
DS00770 Sept. 17, 2010

© 1998-2013 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

  • Reprints
  • Print
  • Share on:

  • Email

Advertisement


Text Size: smaller largerlarger